[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 913
Citations 0
Correction
March 6, 2013

Incomplete Conflicts of Interest Disclosures in: Fish Oil and Postoperative Atrial Fibrillation: The Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) Randomized Trial

JAMA. 2013;309(9):876. doi:10.1001/jama.2013.537

Incomplete Conflicts of Interest Disclosures: In the Original Contribution entitled “Fish Oil and Postoperative Atrial Fibrillation: The Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) Randomized Trial” published in the November 21, 2012, issue of JAMA (2012;308[19]:2001-2011), information reported by the authors for the Conflicts of Interest Disclosures section was inadvertently omitted. The text in that section should have read as follows: “All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Mozaffarian reported receiving a grant from GlaxoSmithKline, Sigma Tau, the National Institutes of Health, and Pronova for a not-for-profit randomized clinical trial of fish oil supplements for prevention of postsurgical complications; serving on the Unilever North America Scientific Advisory Board; serving as a consultant for FoodMinds and McKinsey Health Systems Institute; receiving royalties from UpToDate; and receiving payment for development of educational presentations from the International Life Sciences Institute, Bunge, SPRIM, Pollack Institute, and Nutrition Impact. Dr Marchioli reported receiving grants from GlaxoSmithKline, Pronova Biopharma, and Sigma Tau; serving as a consultant for Catabasis; receiving grants or grants pending from Sigma Tau, SPA, GlaxoSmithKline, Novartis, Amgen SpA, the Myeloproliferative Disorders Research Consortium, AIFA, Ospedali Riuniti di Bergamo, Associazione Italiana Linformi, Pronova, Menarini, and General Electric; and receiving payment for lectures from Ferrer, Pronova, and Sigma Tau. Dr Macchia reported receiving a grant for study coordination in Argentina, reimbursement for steering committee meetings, and a grant or grant pending from SPA and Sigma Tau for conducting the FORWARD clinical trial. Ms Silletta reported receiving a grant from GlaxoSmithKline, Sigma Tau, the National Institutes of Health, and Pronova. Dr Ferrazzi reported receiving a grant, consulting fees, and travel support from GlaxoSmithKline, Sigma Tau, the National Institutes of Health, and Pronova. Dr Latini reported receiving a grant from Partners Association; receiving travel support from Roche Diagnostics; serving as a board member for Alere; serving as a consultant for Fisiopharma and Farmatex; receiving payment for lectures from Novartis; and receiving travel/accommodations/meeting expenses from Roche Diagnostics. Dr Libby reported receiving a grant and travel support from GlaxoSmithKline, Sigma Tau, the National Institutes of Health, and Pronova; and serving as a consultant for AstraZeneca, Novartis, and Pfizer. Dr Lombardi reported receiving travel support and participation fees for review activities from Istituto Mario Negri Sud. Dr Page reported receiving a grant and travel support from Partners. Dr Tavazzi reported receiving travel support from GlaxoSmithKline, Sigma Tau, the National Institutes of Health, and Pronova; serving as a board member for Servier, St Jude Medical, Boston Scientific, Medtronic, Vifor Pharma, and Cardiorentis; and receiving payment for lectures from Servier. Dr Tognoni reported receiving a grant from GlaxoSmithKline, Sigma Tau, the National Institutes of Health, and Pronova; receiving grants or grants pending from Sigma Tau; and receiving payment for lectures from Ferrer, Pronova, SPA (Società Prodotti Antibiotici), and Sigma Tau. No other authors reported disclosures.” This article has been corrected online.

×